From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor ...

The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...

Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...

The trial, also referred to as KEYNOTE-905, met its primary end point of EFS, resulting in a 60% reduction in the risk of tumor recurrence, progression, or death of patients treated with neoadjuvant ...

Investigators evaluated stromal content in the tumor microenvironment as a marker for bladder cancer prognosis, including disease-free survival and overall survival.

The "Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" report highlights significant R&D opportunities with over 20 companies and 22 pipeline drugs, focusing on innovative treatments like ...

The perioperative enfortumab vedotin plus pembrolizumab (EV-P) substantially increased the frequency of adverse events (AEs), ...

Identifying biomarkers that simultaneously reflect inflammation and coagulation status is crucial for early prediction and prevention of VTE in high-risk populations.

Today’s ACT Brief highlights how artificial intelligence is transforming trial data management, why biotechs are embracing parallel execution to accelerate development, and new Phase III results ...